慢性阻塞性肺疾病治疗指南及实施问题
Guidelines for chronic obstructive pulmonary disease treatment and issues of implementation.
作者信息
Rabe Klaus F
机构信息
Department of Pulmonology, C3-P, Leiden University Medical Center, Albinusdreef 2-Postbus 9600, Leiden 2300 RC, The Netherlands.
出版信息
Proc Am Thorac Soc. 2006 Sep;3(7):641-4. doi: 10.1513/pats.200604-099SS.
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Treatment advances over the last decade, although limited, have precipitated the development of clinical practice guidelines, with the aim of improving the quality of care received by patients through fostering evidence-based decision making and accelerating the application of new advances to everyday practice. Of the COPD guidelines that have been developed, those developed through the Global Initiative for Chronic Obstructive Lung Disease (GOLD), initially a joint activity between the U.S. National Heart, Lung, and Blood Institute and the World Health Organization, and the National Institute of Clinical Excellence (NICE) in the United Kingdom have both published their methods for evaluation of evidence. These comprehensive guidelines cover all aspects of the disease, with the aim of providing the basis for local care pathways. The guideline development process includes evaluation of the evidence, development of the guideline, and dissemination of the findings. Efforts to enhance guideline effectiveness have focused on improving the methods and approaches to implementation, which requires an appreciation of the issues that stop translation of guideline definitions of best practice into improved patient care. A variety of questions remain unanswered in the clinical management of COPD, including the definition of outcome measures that move beyond lung function, the potential application of multidimensional grading systems that assess respiratory and systemic expressions of COPD and that could possibly better categorize and predict outcome in these patients, and the impact of new clinical trial findings. Large ongoing outcome studies may also have an effect on defining best practice within future guideline recommendations.
慢性阻塞性肺疾病(COPD)是全球发病和死亡的主要原因。过去十年间,尽管治疗进展有限,但仍促成了临床实践指南的制定,目的是通过促进循证决策以及加快将新进展应用于日常实践,来提高患者所接受治疗的质量。在已制定的COPD指南中,由慢性阻塞性肺疾病全球倡议组织(GOLD,最初是美国国立心肺血液研究所与世界卫生组织的联合项目)以及英国国家临床优化研究所(NICE)制定的指南都已公布了其证据评估方法。这些全面的指南涵盖了该疾病的各个方面,旨在为地方护理路径提供依据。指南制定过程包括证据评估、指南制定以及研究结果的传播。提高指南有效性的努力主要集中在改进实施方法和途径上,这需要了解阻碍将最佳实践的指南定义转化为改善患者护理的问题。在COPD的临床管理中,仍有各种问题未得到解答,包括超越肺功能的结局指标的定义、评估COPD呼吸和全身表现且可能更好地对这些患者进行分类和预测结局的多维分级系统的潜在应用,以及新临床试验结果的影响。正在进行的大型结局研究也可能会对未来指南建议中最佳实践的定义产生影响。